OncoSec Medical Incorporated (NASDAQ: ONCS) ('OncoSec'), a clinical-stage biotechnology company, announced on Friday that it has named Robert H. Arch, PhD, as its new president and chief executive officer.

Dr Arch has served as Head of Research at Elpiscience Biopharma, Ltd and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research. He has more than 28 years of experience that extends from academia to the pharmaceutical industry, including positions at Novartis, Takeda, GlaxoSmithKline, and Pfizer.

Kevin Smith, Board member of OncoSec, said: "On behalf of the Board of Directors, we are excited to welcome Robert to OncoSec and confident he will bring a focus on long-term value creation. Robert is uniquely qualified based on his executive experience in leading cross-functional pipeline strategy, and building and leading discovery teams across multiple geographic regions throughout his career."